Discover our impact all over the world.

Numbers displayed on the map are a representation of the activity in each country. Once you use the filter selections below, you will have the opportunity to explore projects and faculty in each country.

Projects + Faculty = Activity Number

##

Overview

Projects 709
Countries 136
Faculty 422
Health Topics 132

Filter from the selections below

Clear All Filters

Tribendimedine Consortium

 Tribendimidine (TrBD) is a widely studied anthelmintic drug supported by more than 20 years of clinical research and 10 years of approved use in China. Together with a consortium of government, nonprofit, and commercial partners, PATH intends to seek US Food and Drug Administration (FDA) approval for TrBD as a significantly improved treatment for hookworm infections. FDA approval is the initial step in a plan to incorporate TrBD in mass deworming campaigns in low-resource settings. To execute the project, PATH is leading a TrBD Consortium that includes the National Institute of Parasitic Diseases at the Chinese Center for Disease Control and Prevention, which is credited with the development of TrBD in China; TrBD manufacturer Shandong Xinhua Pharmaceutical Company; and Swiss Tropical and Public Health Institute. Michael provides epidemiologic and statistical support for the series of clinical trials required for this great endeavor. 

This is an ongoing project. 

Active Dates 
01/01/2017
Faculty Involved 
Organizations